Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-14T22:39:35.427Z Has data issue: false hasContentIssue false
  • English
  • Français

Risk of Postdischarge Infection with Vancomycin-Resistant Enterococcus after Initial Infection or Colonization

Published online by Cambridge University Press:  02 January 2015

Rupak Datta  and
Susan S. Huang
Rupak Datta*
Affiliation:
Division of Infectious Diseases and Health Policy Research Institute, University of California Irvine School of Medicine, Irvine, California
Susan S. Huang
Affiliation:
Division of Infectious Diseases and Health Policy Research Institute, University of California Irvine School of Medicine, Irvine, California Channing Laboratory, Brigham and Women's Hospital, Boston, Massachusetts
*
University of California Irvine School of Medicine, Health Policy Research Institute, 100 Theory, Suite 110, Irvine, CA 92697, (rdatta@uci.edu)
Get access Rights & Permissions [Opens in a new window]

Abstract

Postdischarge risks of vancomycin-resistant Enterococcus (VRE) infection among carriers are unknown. We conducted a retrospective cohort study of 199 patients newly detected as VRE carriers. Fifteen patients (8%) developed 27 VRE infections in the 18 months after detection. Among 10 postdischarge infections, 2 involved bacteremia and 3 resulted in readmission.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 31 , Issue 12 , December 2010 , pp. 1290 - 1293
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.DeFrances, CJ, Lucas, CA, Buie, VC, Golosinskiy, A. National Health Statistics Report, No. 5: 2006 National Hospital Discharge Survey. Centers for Disease Control and Prevention website, http://www.cdc.gov/nchs/data/nhsr/nhsr005.pdf. Published July 30, 2008. Accessed October 19, 2010.Google Scholar
2.Patel, R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother 2003;51(suppl 3):iii13–iii21.Google Scholar
3.Zaas, AK, Song, X, Tucker, P, Perl, TM. Risk factors for development of vancomycin-resistant enteroccocal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 2002;35:1139–1146.CrossRefGoogle Scholar
4.Edmond, MB, Ober, IF, Weinbaum, DL, Pfaller, MA, Hwang, T, Sanford, MD, Wenzel, RP. Vancomycin-resistant Enterococcus faeium bacteremia: risk factors for infection. Clin Infect Dis 1995;20:1126–1133.Google Scholar
5.Kuehnert, MJ, Jernigan, JA, Pullen, AL, Rimland, D, Jarvis, WR. Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol 1999;20:660–663.CrossRefGoogle ScholarPubMed
6.Byers, KE, Anglim, AM, Anneski, CJ, Farr, BM. Duration of colonization with vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2002;23:207–211.CrossRefGoogle ScholarPubMed
7.Montecalvo, MA, de Lencastre, H, Carraher, M, et al.Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1995;16:680–685.Google Scholar
8.Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing—Seventeenth Informational Supplement. Wayne, PA: CLSI; 2007. CLSI document M100-S17.Google Scholar
9.Horan, TC, Gaynes, RP. Surveillance of nosocomial infections. In: Mayhall, CG, ed. Hospital Epidemiology and Infection Control. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2004:1659–1702.Google Scholar
10.Hayden, MK. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin Infect Dis 2000;31:1058–1065.Google Scholar